Bristol-Myers Squibb stock
Price history
+30.43% over the period1 year: from $48.63 (November 13, 2025) to $63.43 (November 13, 2026), +30.43%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $63.43 |
| October 30, 2026 | $62.48 |
| September 30, 2026 | $62.40 |
| August 31, 2026 | $66.81 |
| July 31, 2026 | $65.31 |
| June 30, 2026 | $57.62 |
| May 29, 2026 | $57.18 |
| April 30, 2026 | $60.59 |
| March 31, 2026 | $60.65 |
| February 27, 2026 | $62.37 |
| January 30, 2026 | $55.05 |
| December 31, 2025 | $53.94 |
| November 28, 2025 | $49.20 |
| November 13, 2025 | $48.63 |
At a glance
The company
Discovers, develops and markets biopharmaceutical products for oncology, hematology, immunology, cardiovascular and neuroscience indications
Latest results
Quarter to September 30, 2026 · EPS $1.35 (estimate $1.09)
TickerLandia's take on Bristol-Myers Squibb
- Priced as usual relative to earnings: P/E on the latest fiscal year 18 vs a median of 21 over its last 8 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 14 vs 42 (−67%) in a group of 10.
- Strong point: Dividend (72/100 in its group). Weak point: Earnings stability (20/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−7.59% from the 52-week high
Analysts · 28 analysts
Average target$65.25+2.87% vs. price
Buy 11 · Hold 16 · Sell 1 · Buy
TickerLandia Fingerprint: Bristol-Myers Squibb
Compared with similar companies: low earnings stability.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow29
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 14.1 15 Forward P/E 9.47 6 Price/book 5.54 56 Price/sales 2.59 38 EV/EBITDA 8.87 30 Profitabilityaverage59
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 32.4% 54 Gross margin 70.5% 22 ROE 44.0% 81 ROA 10.9% 70 Net margin 18.5% 66 Earnings stabilitylow20
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.4% 34 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 6 Growthlow39
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +1.45% 26 Revenue growth (year over year) +6.90% 46 Earnings growth (year over year) −2.80% 44 Financial strengthlow32
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.92 26 Current ratio 1.59 66 Interest coverage 7.95 26 Debt/equitycounts in reverse: lower means more financial strength 1.91 10 Dividendhigh72
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 37 years 90 Dividend yield 4.0% 81 Payout ratio 55.9% 44 Market momentumstrong61
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +1.19% 49 Distance from 200-day average +5.12% 56 Relative strength (6 months) +10.74% 64 1-year return +30.43% 73 Risklow25
How much the price swings.
Metric Value Position in group Volatility (60 days) 27.6% 32 Beta (1 year) 0.23 28 Maximum drawdown (12 months) 16.8% 15
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Bristol-Myers Squibb is priced as in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Bristol-Myers Squibb's P/E today is 18.3, in line with the median of its last 8 fiscal years (21.0; between 13.3 and 100.5 from 2016 to 2025). Bristol-Myers Squibb's P/E (trailing 12 months): 14.1, −67% against the median of a group of 10 similar companies (42.3).
Compared with 10 similar companies
| Metric | Bristol-Myers Squibb | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 14.1 | Low | |
| Forward P/E | 9.47 | Low | |
| Operating margin | 32.4% | Middle | |
| ROE | 44.0% | High | |
| Debt/equity | 1.91 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Bristol-Myers Squibb. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$12.97B
Latest quarter · Q2 2026
Net income
$3.32B
Latest quarter · Q2 2026
Quarterly net margin
25.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $129.66B
- P/E
- 14.1
- EPS
- $4.51
- Volume
- 9.27M
- Daily trading
- €568.43M
- Dividend yield
- 3.97%
- Last ex-dividend on October 2, 2026
How Bristol-Myers Squibb is changing
All resultsRevenue grew 2.5% a year on average over the last 5 years
Operating margin rose from 19.8% to 31.2%
Shares outstanding down 9.7% in 5 years
Returns
Bristol-Myers Squibb returns with dividends
$1,000 invested in Bristol-Myers Squibb 5 years ago, on November 15, 2021, would be worth $1,308 today with dividends reinvested: +30.83% in total, +5.53% per year. On price alone it would be $1,064 (+6.39%).
| Period | Bristol-Myers Squibb | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +11.93% | −3.12% | $1,119 |
| 6 months | +12.48% | +1.58% | $1,125 |
| Year to date | +17.59% | +10.46% | $1,176 |
| 1 year | +36.20% | +12.23% | $1,362 |
| 3 years | +45.65% | +71.41% | $1,457 |
| 5 years | +30.83% | +61.48% | $1,308 |
| 10 years | +60.15% | +249.40% | $1,602 |
Over the last 6 months it has done better than 40% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Bristol-Myers Squibb: technical analysis
Bristol-Myers Squibb is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 21.8% below its highest close since January 2, 1990 ($81.13, December 2, 2022).
- Trend
- Upward
- RSI (14 sessions)
- 56
- Between 30 and 70
- vs 200-session average
- +5.12%
Support and resistance
Price areas where Bristol-Myers Squibb has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$68.33+7.72%3 touches, last on September 3, 2026
- Resistance$63.86+0.68%2 touches, last on October 22, 2026
- Last price$63.43
- Support$62.54−1.40%4 touches, last on August 12, 2026
- Support$60.42−4.74%5 touches, last on October 29, 2026
- Support$59.06−6.90%2 touches, last on June 30, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.23
- Volatility (60 sessions, annualised)
- 27.6%
- Largest fall in the last year
- −16.77%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Bristol-Myers Squibb: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Bristol-Myers Squibb has been November: +2.67% on average, positive in 25 years out of 36. The weakest has been January: −1.99% on average, positive in 15 years out of 36.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −1.99% | −1.45% | 15 of 36 |
| February | +0.67% | +0.62% | 22 of 37 |
| March | +0.25% | +1.72% | 22 of 37 |
| April | −1.18% | −0.88% | 17 of 37 |
| May | +1.32% | +0.68% | 21 of 37 |
| June | +0.66% | +1.67% | 22 of 37 |
| July | −0.16% | −0.97% | 14 of 37 |
| August | −0.22% | +1.30% | 21 of 37 |
| September | +0.96% | +0.45% | 19 of 37 |
| October | +2.08% | +1.95% | 22 of 37 |
| November | +2.67% | +1.84% | 25 of 36 |
| December | +2.16% | +2.28% | 22 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Bristol-Myers Squibb and its competitors
Doctors and patients treated for cancer, blood disorders, immune diseases, heart conditions and neurological illnesses are the core of the business of Bristol-Myers Squibb Company, which discovers, develops, manufactures and sells biopharmaceutical drugs worldwide. Key brands include Opdivo, Eliquis, Revlimid, Breyanzi and Zeposia, with products such as Cobenfy for schizophrenia and Camzyos for obstructive heart disease. Sales reach customers through a broad network of intermediaries and care providers, and the United States accounts for 69.1% of revenue, with 28.7% from other countries and 2.3% from other regions.
- Headquarters
- Princeton, United States
- Employees
- 32,500
- Founded
- 1887
- Chief executive
- Christopher Boerner
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Bristol-Myers SquibbBMY | $129.66B | 32.4% | 14.1 | +12.48% |
| PfizerPFE | $164.67B | 29.1% | 41.3 | +11.29% |
| Gilead SciencesGILD | $208.48B | 38.2% | — | +26.33% |
| AmgenAMGN | $251.89B | 34.1% | 27.0 | +38.41% |
| Merck & Co.MRK | $364.26B | 35.2% | 147.8 | +30.24% |
| BiogenBIIB | $37.46B | 23.5% | 108.3 | +23.89% |
Same industry or related industries, similar size. Compare Bristol-Myers Squibb with its competitors · Full profile
